(T 02) Long-Term Safety, Tolerability, and Efficacy of Atogepant for the Preventive Treatment of Migraine: Final Results from a Phase 3, Open-Label, 156-Week, Long-Term Safety Extension Study

Presenting Author(s)

Messoud Ashina, n/a

Professor of Neurology and Chief Physician
Copenhagen University Hospital–Rigshospitalet
Glostrup, Hovedstaden, United States

Sait Ashina, MD

Assistant Professor of Neurology and Anesthesia
Harvard Medical School
Boston, Massachusetts, United States
CT

Cristina Tassorelli, MD, PhD

Director of the Headache Science Centre and of the Neurorehabilitative Unit at the IRCCS C. Mondino
University of Pavia, Pavia, Italy
Pavia, Lombardia, United States
Peter Goadsby, PhD DSc FRACP FRCP FMedSci FRS

Professor of Neurology and Honorary Consultant Neurologist
University of Leeds UK, King Abdullah University of Science and Technology, Saudi Arabia,NIHR King’s Clinical Research Facility, & SLaM Biomedical Research Centre, and The Wolfson Sensory, Pain and Regeneration Centre (SPaRC), Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK
London, United Kingdom
SC

Soo-Jin Cho, MD

Professor
Department of Neurology, Dongtan Sacred Heart Hospital, College of Medicine, Hallym University, 18450, Republic of Korea
Hwaseong, United States
RM

Rebeka Man, PhD

AbbVie, United States
HG

Hua Guo, PhD

AbbVie, United States
EC

Eric Cohen, MD

AbbVie
Chicago, Illinois, United States
KN

Krisztian Nagy, MD, MSc

AbbVie
North Chicago, Illinois, United States
JS

Jonathan H. H. Smith, MD

AbbVie
Chicago, Illinois, United States